Determination of Probiotics Prescription Indications in Patients with Irritable Bowel Syndrome (Materials of the Expert Council and Literature Review)

V. Ivashkin, I. Maev, O. P. Alekseeva, S. Alekseenko, N. Korochanskaya, E. Poluektova, V. Simanenkov, A. Trukhmanov, I. Khlynov, V. Tsukanov, O. Shifrin, T. Lapina, R. Maslennikov, A. Ulyanin
{"title":"Determination of Probiotics Prescription Indications in Patients with Irritable Bowel Syndrome (Materials of the Expert Council and Literature Review)","authors":"V. Ivashkin, I. Maev, O. P. Alekseeva, S. Alekseenko, N. Korochanskaya, E. Poluektova, V. Simanenkov, A. Trukhmanov, I. Khlynov, V. Tsukanov, O. Shifrin, T. Lapina, R. Maslennikov, A. Ulyanin","doi":"10.22416/1382-4376-2022-32-2-9-18","DOIUrl":null,"url":null,"abstract":"Aim. To review the main indications for probiotics prescription in patients with irritable bowel syndrome and to present the materials of an Expert Council, which was held on 18 March 2022 in Moscow.Key points. Gut microbiota disturbance is an integral part of irritable bowel syndrome (IBS) pathogenesis. Changes of colonic microbiota composition are associated with its functional potential modification, which leads to an increasing of the pro-inflammatory immune response, as well as to an exacerbation of the disease symptoms and quality of life decreasing in patients with IBS. The novel coronavirus infection (COVID-19) is an independent risk factor for both exacerbation and onset of IBS, which predispose to increase IBS incidence. Correction of gut microbiota composition with probiotics seems to be a promising therapeutic target for IBS treatment optimizing. The optimal probiotic should be effective, safe, strain-specific, and its dose and duration of administration should be confirmed by the results of clinical studies. Some of the probiotics with proven efficacy in IBS are Alflorex® and Enterol®.Conclusion. Prescription of certain probiotics in IBS is advisable to normalize the frequency and consistency of stools, relieve abdominal pain and bloating, as well as improve patients’ quality of life.","PeriodicalId":33798,"journal":{"name":"Rossiiskii zhurnal gastroenterologii gepatologii koloproktologii","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rossiiskii zhurnal gastroenterologii gepatologii koloproktologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22416/1382-4376-2022-32-2-9-18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Aim. To review the main indications for probiotics prescription in patients with irritable bowel syndrome and to present the materials of an Expert Council, which was held on 18 March 2022 in Moscow.Key points. Gut microbiota disturbance is an integral part of irritable bowel syndrome (IBS) pathogenesis. Changes of colonic microbiota composition are associated with its functional potential modification, which leads to an increasing of the pro-inflammatory immune response, as well as to an exacerbation of the disease symptoms and quality of life decreasing in patients with IBS. The novel coronavirus infection (COVID-19) is an independent risk factor for both exacerbation and onset of IBS, which predispose to increase IBS incidence. Correction of gut microbiota composition with probiotics seems to be a promising therapeutic target for IBS treatment optimizing. The optimal probiotic should be effective, safe, strain-specific, and its dose and duration of administration should be confirmed by the results of clinical studies. Some of the probiotics with proven efficacy in IBS are Alflorex® and Enterol®.Conclusion. Prescription of certain probiotics in IBS is advisable to normalize the frequency and consistency of stools, relieve abdominal pain and bloating, as well as improve patients’ quality of life.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肠易激综合征患者益生菌处方指征的确定(专家委员会资料及文献综述)
的目标。回顾肠易激综合征患者益生菌处方的主要适应症,并介绍于2022年3月18日在莫斯科举行的专家委员会的材料。要点。肠道菌群紊乱是肠易激综合征(IBS)发病机制的重要组成部分。结肠菌群组成的改变与其功能潜在的改变有关,从而导致促炎免疫反应的增加,以及肠易激综合征患者疾病症状的加重和生活质量的下降。新型冠状病毒感染(COVID-19)是IBS加重和发病的独立危险因素,易增加IBS发病率。用益生菌纠正肠道菌群组成似乎是优化肠易激综合征治疗的一个有希望的治疗靶点。最佳的益生菌应是有效、安全、菌株特异性的,其剂量和给药时间应由临床研究结果确定。一些已证实对肠易激综合征有效的益生菌是Alflorex®和Enterol®。肠易激综合征患者宜服用一定的益生菌,使大便的频率和稠度正常化,减轻腹痛和腹胀,提高患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
44
审稿时长
8 weeks
期刊最新文献
Modern Possibilities of Using Lactulose in Clinical Practice A Case of Medullary Carcinoma of the Jejunum Combined with the Intestinal Lymphangiectasia Accompanied by the Malabsorption Syndrome Esophageal Lichen Planus as a Cause of Dysphagia: Literature Review and Clinical Observation Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion Immediate Results of Colonic Flat Epithelial Neoplasms Removal Using Diathermic Snare Endoscopic Mucosal Resection and Mucosectomy Combined with Dissection in the Submucosal Layer: Comparative Assessment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1